Diabetes, Insulin Resistance and Glucose Metabolism in HIV Infection and its Treatment

The Epidemiology of Diabetes Mellitus: Second Edition

Volumn , Issue , 2008, Pages 665-675

  Samaras, Kathy ^a   Chisholm, Don J ^a  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Diabetes and HIV infection prevalence; Dyslipidemia and HAART metabolic complications; HIV 1 infection and highly active antiretroviral therapy (HAART); HIV infected HAART hyperglycemia recipients; HIV infected HAART recipients and lipoatrophy; Mitochondrial dysfunction in insulin resistance; Nucleoside reverse transcriptase inhibitors (NRTIs)

Indexed keywords

EID: 84876013172     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470779750.ch40     Document Type: Chapter

References (63)

1. Kilby, J.M. and Tabereaux, P.B. (1998) Severe hyperglycemia in an HIV clinic: preexisting versus drug-associated diabetes mellitus. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 17, 46-50.
2. Coyle, P., Carr, A.D., Depczynski, B.B. and Chisholm, D.J. (1996) Diabetes mellitus associated with pentamidine use in HIV-infected patients. The Medical Journal of Australia, 165, 587-8.
3. Ubukata, E., Mokuda, O., Nagata, M. et al. (1997) A pentamidine-treated acquired immunodeficiency syndrome patient associated with sudden onset diabetes mellitus and high tumor necrosis factor alpha level. Journal of Diabetes and its Complications, 11, 256-8.
4. Lu, C.P., Wu, H.P., Chuang, L.M. et al. (1995) Pentamidine-induced hyperglycemia and ketosis in acquired immunodeficiency syndrome. Pancreas, 11, 315-16.
5. Carr, A., Samaras, K., Burton, S. et al. (1998) A syndrome of peripheral lipodystrophy, hyperlipi-daemia and insulin resistance due to HIV protease inhibitors. AIDS, 12, F51-8.
6. Carr, A., Samaras, K., Thorisdottir, A. et al. (1999) Natural history, diagnosis and prediction of HIV protease inhibitor-induced lipodystrophy, hyperlip-idaemia and diabetes mellitus. Lancet, 353, 2094-9.
7. Gan, S.K., Samaras, K., Thompson, C.H. et al. (2002) Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy. Diabetes, 51, 3163-9.
8. Carr, A., Workman, C., Carey, D. et al. (2004) Rosiglitazone for the treatment of HIV lipoatrophy: a randomised, double-blind, placebo-controlled trial. Lancet, 363, 429-38.
9. Carr, A., Miller, J., Law, M. and Cooper, D.A. (2000) A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS, 14, F25-32.
10. Thiebaut, R., Daucourt, V., Mercie, P. et al. (2000) Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Clinical Infectious Diseases, 31, 1482-7.
11. Mallal, S.A., John, M., Moore, C.B. et al. (2000) Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS, 14, 1309-16.
12. Grinspoon, S. and Carr, A. (2005) Cardiovascular risk and body-fat abnormalities in HIV-infected adults. The New England Journal of Medicine, 352, 48-62.
13. Mallon, P.W., Miller, J., Cooper, D.A. and Carr, A. (2003) Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS, 17. 971-9.
14. HIV Lipodystrophy Case Definition Study Group (2003) An objective case definition of lipodystrophy in HIV-infected adults: a case control study. Lancet, 361, 726-35.
15. Martinez, E., Mocroft, A., Garcia-Viejo, M.A. et al. (2001) Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet, 357, 592-8.
16. Heath, K.V., Hogg, R.S., Singer, J. et al. (2002) Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based chort. Journal of Acquired Immune Deficiency Syndromes, 30, 440-7.
17. El-Sadr, W.M., Mullin, C.M., Carr, A. et al. (2005) Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Medicine, 6, 114-21.
18. Brown, T.T., Cole, S.R., Li, X. et al. (200) Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Archives of Internal Medicine, 165, 1179-84.
19. Howard, A.A., Floris-Moore, M., Arnsten, J.H. et al. (2005) Disorders of glucose metabolism among HIV-infected women. Clinical Infectious Diseases, 40, 1492-9.
20. Justman, J.E., Benning, L., Danoff, A. et al. (2003) Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. Journal of Acquired Immune Deficiency Syndromes, 32, 298-302.
21. Salehian, B., Bilas, J., Bazargan, M. and Abbasian, M. (2005) Prevalence and incidence of diabetes in HIV-infected minority patients on protease inhibitors. Journal of the National Medical Association, 97, 1088-92.
22. Mehta, S.H., Moore, R.D., Thomas, D.L. et al. (2003) The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons. Journal of Acquired Immune Deficiency Syndromes, 33, 577-84.
23. Amorosa, V., Synnestvedt, M., Gross, R. et al. (2005) A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia. Journal of Acquired Immune Deficiency Syndromes, 39, 557-61.
24. Yazicioglu, G., Isitan, F., Altunbas, H. et al. (2004) Insulin resistance in chronic hepatitis C. International Journal of Clinical Practice, 58, 1020-2.
25. Panz, V.R. and Joffe, B.I. (1999) Impact of HIV infection and AIDS on prevalence of type 2 diabetes in South Africa in 2010 (Letter). British Medical Journal, 318, 1351A.
26. Levitt, N.S. and Bradshaw, D. (2006) The impact of HIV/AIDS on type 2 diabetes prevalence and diabetes healthcare needs in South Africa: projections for 2010 (Letter). Diabetic Medicine, 23, 103-4.
27. Carr, A., Samaras, K., Chisholm, D.J. and Cooper, D.A. (1998) Pathogenesis of protease-inhibitor-associated syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance. Lancet, 351, 1881-3.
28. Gan, S.K., Samaras, K., Carr, A. and Chisholm, D.J. (2001) Antiretroviral therapy, insulin resistance and lipodystrophy. Diabetes, Metabolism and Obesity, 3, 67-71.
29. McGarry, J.D. (2002) Banting Lecture 2001: Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes, 51, 7-18.
30. Wollheim, C.B. (2000) Beta-cell mitochondria in the regulation of insulin secretion: a new culprit in type II diabetes. Diabetologia, 43, 265-77.
31. Samaras, K., Nguyen, T.V., Jenkins, A.B. et al. (1999) Clustering of insulin resistance, total and central abdominal fat: are the relationships due to same genes or same environment? Twin Research, 2, 218-25.
32. Pan, D.A., Lillioja, S., Kriketos, A.D. et al. (1997) Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes, 46, 983-8.
33. 13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes, 48, 1600-6.
34. Hadigan, C., Kamin, D., Liebau, J. et al. (2006) Depot-specific regulation of glucose uptake and insulin sensitivity in HIV-lipodystrophy. American Journal of Physiology. Endocrinology and Metabolism, 290, E289-98.
35. Nolte, L.A., Yarasheski, K.E., Kawanaka, K. et al. (2001) The HIV protease inhibitor indinavir decreases insulin-and contraction-stimulated glucose transport in skeletal muscle. Diabetes, 50, 1397-401.
36. Noor, M.A., Lo, J.C., Mulligan, K. et al. (2001) Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS, 15, F11-18.
37. Murata, H., Hruz, P.W. and Mueckler, M. (2002) Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. AIDS, 16, 859-63.
38. Tong, Q., Sankale, J.L., Hadigan, C.M. et al. (2003) Regulation of adiponectin in human immunodeficiency virus-infected patients: relationship to body composition and metabolic indices. The Journal of Clinical Endocrinology and Metabolism, 88, 1559-64.
39. Falasca, K., Manigrasso, M.R., Racciatti, D. et al. (2006) Associations between hypertriglyceridemia and serum ghrelin, adiponectin, and IL-18 levels in HIV-infected patients. Annals of Clinical and Laboratory Science, 36, 59-66.
40. Haugaard, S.B., Andersen, O., Dela, F. et al. (2005) Defective glucose and lipid metabolism in human immunodeficiency virus-infected patients with lipodystrophy involve liver, muscle tissue and pancreatic beta-cells. European Journal of Endocrinology, 152, 103-12.
41. Petersen, K.F., Dufour, S., Befroy, D. et al. (2004) Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. The New England Journal of Medicine, 350, 664-71.
42. Lo, J.C., Kazemi, M.R., Hsue, P.Y. et al. (2005) The relationship between nucleoside analogue treatment duration, insulin resistance, and fasting arte-rialized lactate level in patients with HIV infection. Clinical Infectious Diseases, 41, 1335-40.
43. Bastard, J.P., Caron, M., Vidal, H. et al. (2002) Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet, 359, 1026-31.
44. Caron, M., Auclair, M., Vigouroux, C. et al. (2001) The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes, 50, 1378-88.
45. Dowell, P., Flexner, C., Kwiterovich, P.O. and Lane, M.D. (2000) Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. The Journal of Biological Chemistry, 275, 41325-32.
46. Lenhard, J.M., Furfine, E.S., Jain, R.G. et al. (2000) HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. Antiviral Research, 47, 121-9.
47. Caron, M., Auclair, M., Sterlingot, H. et al. (2003) Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. AIDS, 17, 2437-44.
48. Lagathu, C., Bastard, J.P., Auclair, M. et al. (2004) Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro. Antiviral Therapy, 9, 911-20.
49. Mallon, P.W.G., Unemori, P., Sedwell, R. et al. (2005) In vivo, nucleoside reverse transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of mitochondrial DNA depletion. Journal of Infectious Diseases, 191, 1686-96.
50. Hadigan, C., Yawetz, S., Thomas, A. et al. (2004) Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Annals of Internal Medicine, 140, 786-94.
51. Mallon, P.W.G., Miller, J., Kovacic, J. et al. (2006) Changes in body composition and surrogate markers of cardiovascular disease in hypercholes-terolaemic HIV-infected men treated with pravastatin-a randomised, placebo-controlled study. AIDS, 20, 1003-10.
52. Miller, J., Brown, D., Amin, J. et al. (2002) A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitoras-sociated hypertriglyceridaemia. AIDS, 16, 2195-200.
53. Hadigan, C., Corcoran, C., Basgoz, N. et al. (2000) Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. The Journal of the American Medical Association, 284, 472-7.
54. Driscoll, S.D., Meininger, G.E., Lareau, M.T. et al. (2004) Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients. AIDS, 18, 465-73.
55. Driscoll, S.D., Meininger, G.E., Ljungquist, K. et al. (2004) Differential effects of metformin and exercise on muscle adiposity and metabolic indices in human immunodeficiency virus-infected patients. The Journal of Clinical Endocrinology and Metabolism, 89, 2171-8.
56. Martinez, E., Conget, I., Lozano, L. et al. (1999) Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS, 13, 805-10.
57. Carr, A., Hudson, J., Chuah, J. et al. (2001) HIV protease inhibitor substitution in patients with lipodystrophy: a randomised, controlled, open-label, multicentre study. AIDS, 15, 1811-22.
58. Martin, A., Smith, D., Carr, A. et al. (2004) Progression of lipodystrophy (LD) with continued thymidine analogue usage: long-term follow-up from a randomised clinical trial (The PIILR Study). HIV Clinical Trials, 5, 192-200.
59. Carr, A., Workman, C., Smith, D.E. et al. (2002) Mitochondrial Toxicity (MITOX) Study Group. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomised trial. The Journal of the American Medical Association, 288, 207-15.
60. Martin, A., Smith, D.E., Carr, A. et al. (2004) Mitochondrial Toxicity Study Group. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS, 18, 1029-36.
61. Moyle, G.J., Baldwin, C., Langroudi, B. et al. (2003) A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. Journal of Acquired Immune Deficiency Syndromes, 33, 22-8.
62. John, M., McKinnon, E.J., James, I.R. et al. (2003) Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavirto prevent or reverse lipoatrophy in HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes, 33, 29-33.
63. Friis-Moller, N., Sabin, C.A., Weber, R. et al. (2003) Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. The New England Journal of Medicine, 349, 1993-2003.